ADAPT - A Patient Registry of the Real-world Use of Orenitram®
This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation
⁃ Patients are eligible for the registry if:
• The patient voluntarily gives informed consent to participate in the study.
• The patient must be at least 18 years of age or older.
• The patient is prescribed Orenitram (per the package insert indication), and plans to initiate therapy with this medication or has been receiving Orenitram for 182 or fewer days.
• The patient agrees to dosing, prostacyclin-related AE of interest record keeping, survey participation during designated time periods, and recording any medication changes, use, for the duration of the study.
• The patient has the ability to answer surveys and use the diary in English.
• The patient must have an email address and be willing to access the PRO Portal.